Drug-Drug Interactions among Elderly Patients Hospitalized for Drug Toxicity

JAMA

Volumn 289, Issue 13, 2003, Pages 1652-1658

  Juurlink, David N ^a,b,d   Mamdani, Muhammad ^c,d   Kopp, Alexander ^d   Laupacis, Andreas ^a,b,d   Redelmeier, Donald A ^a,b,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CEFUROXIME; CLARITHROMYCIN; COTRIMOXAZOLE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; INDAPAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; ANTIASTHMATIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; DIURETIC AGENT;

AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CONTROLLED STUDY; DIGITALIS INTOXICATION; DRUG CROSS REACTIVITY; DRUG INTOXICATION; FEMALE; GERIATRIC PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; DRUG CONTRAINDICATION; DRUG INTERACTION; DRUG TOXICITY; STATISTICS;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ASTHMATIC AGENTS; ANTI-INFECTIVE AGENTS; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; CLARITHROMYCIN; DIGOXIN; DIURETICS; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; GLYBURIDE; HOSPITALIZATION; HUMANS; HYPERKALEMIA; HYPOGLYCEMIA; MALE; ONTARIO; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0037414162     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.13.1652     Document Type: Article

References (65)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279: 1200-1205.
2. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27:832-840.
3. Jha AK, Kuperman GJ, Rittenberg E, Teich JM, Bates DW. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf. 2001;10:113-119.
4. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264: 2788-2790.
5. Wynn RL. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)-induced ventricular arrhythmias. Gen Dent. 1993;41:27-29.
6. DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther. 1999; 21:281-295.
7. Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med. 1994;160:321-325.
8. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996;335:290-291.
9. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet. 2000;39:49-75.
10. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol. 2001;96: 1698-1703.
11. Shaoul R, Shahory R, Tamir A, Jaffe M. Comparison between pediatricians and family practitioners in the use of the prokinetic cisapride for gastroesophageal reflux disease in children. Pediatrics. 2002;109: 1118-1123.
12. Langdorf MI, Fox JC, Marwah RS, Montague BJ, Hart MM. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med. 2000;7:1321-1329.
13. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm. 1999;56:1524-1529.
14. Cavuto NJ, Woosley RL, Sale M. Pharmades and prevention of potentially fatal drug interactions. JAMA. 1996;275:1086-1087.
15. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002;40:1161-1171.
16. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash). 2001;41:200-204.
17. Del Fiol G, Rocha BH, Kuperman GJ, Bates DW, Nohama P. Comparison of two knowledge bases on the detection of drug-drug interactions. Proc AMIA Symp. 2000;171-175.
18. Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ. 1999;161:1266-1267.
19. Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc (Wash). 2001;41:159-160.
20. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash). 2001;41:161-165.
21. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377-384.
22. Bates DW, Culten DJ, Laird N, et al. incidence of adverse drug events and potential adverse drug events: implications for prevention: ADE Prevention Study Group. JAMA. 1995;274:29-34.
23. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther. 2001;69:260-265.
24. Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. DICP. 1990;24: 250-251.
25. Christensen LK, Kristensen M. Drug induced changes of the blood glucose lowering effect of oral hypoglycemic agents. Acta Diabetol Lat. 1969;(6 suppl 1):116-136.
26. Potasman I, Bassan H. Hypoglycemia due to interaction between chlorpropamide and cotrimoxazole. Harefuah. 1980;98:78.
27. Brian WR. Hypoglycemic agents. In: Levy R, Thummel K, Trager W, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:529-543.
28. Kirchheiner J, Brockmoller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71:286-296.
29. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002;30:631-635.
30. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72:326-332.
31. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64:123-128.
32. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol. 1998;40:45-46.
33. Brown BA, Wallace RJ, Jr, Griffith DE, Warden R. Clarithromycin-associated digoxin toxicity in the elderly. Clin Infect Dis. 1997;24:92-93.
34. Gooderham MJ, Bolli P, Fernandez PG. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann Pharmacother. 1999;33:796-799.
35. Guerriero SE, Ehrenpreis E, Gallagher KL. Two cases of clarithromycin-induced digoxin toxicity. Pharmacotherapy. 1997;17:1035-1037.
36. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998;158:26-32.
37. Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology. 1991;129:823-831.
38. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
39. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol. 2000;20:268-272.
40. Statistics Canada. Population by age group - Statistics Canada. Available at: http://www.statcan.ca/english/Pgdb/demo31b.htm. Accessed March 10, 2003.
41. Bell CM, Redelmeier DA. Mortality among patients admitted to hospitals on weekends as compared with weekdays. N Engl J Med. 2001;345:663-668.
42. Crighton EJ, Mamdani MM, Upshur RE. A population based time series analysis of asthma hospitalisations in Ontario, Canada: 1988 to 2000. BMC Health Serv Res. 2001;1:7.
43. Mamdani MM, Tu K, van Walraven C, Austin PC, Naylor CD. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ. 2000;162:1421-1424.
44. Mamdani MM, van Walraven C, Bica A, Williams JI, Naylor CD. Is there an association between lipid-lowering drugs and cholecystectomy? Am J Med. 2000;108:418-421.
45. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161:1405-1410.
46. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health. 1998;88:15-19.
47. International Classification of Diseases - Ninth Revision, Hospital Edition. 6th ed. Los Angeles, Calif: Practice Management Information Corp; 2003.
48. Schlesselman JJ, Stolley PD. Case-Control Studies: Design, Conduct, and Analysis. New York, NY: Oxford University Press; 1982.
49. Kleinbaum DG, Kupper LL, Morganstern H. Epidemiologic Research. Belmont, Calif: Lifetime Learning Publication; 1982.
50. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol. 1974;99:325-332.
51. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
52. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864.
53. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12: 485-494.
54. Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging. 1999;14:141-152.
55. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly: a prescription database study. Dan Med Bull. 1998;45:210-213.
56. Tamblyn RM, McLeod PJ, Abrahamowicz M, Laprise R. Do too many cooks spoil the broth? multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ. 1996;154:1177-1184.
57. Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov. 2002;1:37-44.
58. Guzey C, Spigset O. Genotyping of drug targets: a method to predict adverse drug reactions? Drug Saf. 2002;25:553-560.
59. Roberts RL, Begg EJ, Joyce PR, Kennedy MA. How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing. N Z Med J. 2002;115:137-140.
60. Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA. 2001; 286:1607-1609.
61. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
62. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;358:1872-1873.
63. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. EurJ Clin Pharmacol. 1998;54:483-488.
64. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 1997;43:177-181.
65. Lehmann DF. Observation and experiment on the cusp of collaboration: a parallel examination of clinical pharmacology and pharmacoepidemiology. J Clin Pharmacol. 2000;40:939-945.